{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-011512","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.277655+00:00","generated_at":"2026-06-19T13:40:16.551449+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroOne Q1 FY2023 net loss $1.7M; FDA cleared Evo sEEG electrode","bullets":["Product revenue $115K (vs $34K YoY); collaboration revenue $1.46M from Zimmer agreement.","Net loss $1.7M (improved from $2.8M); cash $7.6M, no debt as of Dec 31, 2022.","FDA 510(k) clearance for Evo sEEG electrode; first commercial order shipped to Zimmer Biomet.","Targeting OneRF ablation system 510(k) submission in Q2 calendar 2023; spinal cord stimulation electrodes in pre-clinical.","R&D expense $1.6M (up from $1.1M); SG&A flat at $1.7M; total op ex $3.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-011512","json":"https://secwatch.observer/filing/0001213900-23-011512.json","markdown":"https://secwatch.observer/filing/0001213900-23-011512.md","text":"https://secwatch.observer/filing/0001213900-23-011512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/0001213900-23-011512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/ea173234-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:40:16.551449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90d4d5a59e469c9c0872855fecd6ace9e0e619e3","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for the fiscal first quarter 2023 ended December 31, 2022.","evidence_excerpt":"On February 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/0001213900-23-011512-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal first quarter 2023 ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}